热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易

客户端

　　百济神州（06160）盘中涨逾7%，截至发稿，股价上涨6.01%，现报139.30港元，成交额1.56亿港元。

　　国泰君安此前指出，百济神州泽布替尼高速放量，2025年预计迎来扭亏节点。2023年前三季度泽布替尼销售收入达18.2亿美元，同比+107%，在美国CLL新患中的市场份额已超过竞品伊布替尼、阿卡替尼，位列第一，后续有望在患者的持续滚动积累下维持高速放量趋势；2025年，公司有望实现GAAP经营利润盈亏平衡。另外，公司多款自研产品步入密集收获期。考虑到公司核心产品在欧美放量加速，扭亏节点临近，维持“增持”评级。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：卢昱君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.